This project is a comprehensive research program on the Acquired Immunodeficiency Syndrome (AIDS) and is intended to be part of a nationwide network of a Clinical Studies Group. The proposal consists of three research projects and an administrative core. The first project (Treatment) will evaluate new forms of anti human immunodeficiency virus (HIV) therapy on hemophiliac and intravenous drug abuser populations which are already being followed prospectively in central Massachusetts for their HIV antibody status. Initial studies will concentrate on placebo controlled trials of dideoxynucleoside analogue therapy of asymptomatic HIV seropositive individuals who have shown severe attrition of the immune system (CD4 Helper/Inducer cells less than 400/ul). The second project (Basic Research) proposes to develop assays to assess HIV-specific cytotoxic T lymphocytes (CTL), to study these CTL responses in the peripheral blood of hemophiliac and intravenous drug abusing populations, and to define mechanisms involved in these CTL responses including genetic restriction. The third project (Outreach) aims to develop an educational program on HIV infections for (a) college students through the Worcester Consortium for Higher Education, representing 10 area colleges, and (b) allied health professionals through the Massachusetts network of Area Health Education Centers located across the state outside of the Boston metropolitan area. This research program consisting of projects on HIV Treatment, Basic Research and Education Outreach will be performed in the area of central Massachusetts, a region that has only recently begun to be affected by the AIDS epidemic.

Project Start
1987-09-30
Project End
1992-08-31
Budget Start
1989-09-01
Budget End
1990-08-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Medicine
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Havlir, D; Cheeseman, S H; McLaughlin, M et al. (1995) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537-45
Cheeseman, S H; Havlir, D; McLaughlin, M M et al. (1995) Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 8:141-51
Lai, K K (1994) Attitudes toward childbearing and changes in sexual and contraceptive practices among HIV-infected women. Cleve Clin J Med 61:132-6;quiz 161
Lai, K K (1992) Consent to treatment with zidovudine among HIV-infected patients. Cleve Clin J Med 59:45-7
Koup, R A; Pikora, C A; Mazzara, G et al. (1991) Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol 4:215-23
Alimenti, A; Luzuriaga, K; Stechenberg, B et al. (1991) Quantitation of human immunodeficiency virus in vertically infected infants and children. J Pediatr 119:225-9
Koup, R A; Robinson, J E; Nguyen, Q V et al. (1991) Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS 5:1309-14
Luzuriaga, K; Koup, R A; Pikora, C A et al. (1991) Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr 119:230-6
Koup, R A; Merluzzi, V J; Hargrave, K D et al. (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 163:966-70
Koup, R A; Pikora, C A; Luzuriaga, K et al. (1991) Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J Exp Med 174:1593-600

Showing the most recent 10 out of 11 publications